Product Description
Hydroflumethiazide is an intermediate-acting benzothiadiazine sulfonamide derivative belonging to the class of the thiazide diuretics. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Hydroflumethiazide)
Mechanisms of Action: NCCT Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Approved
Approved Countries: India | Ireland | Italy | New Zealand | Taiwan
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| A6821003 | N/A |
Withdrawn |
Hypertension |
2015-02-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|